Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06313372
Other study ID # CA2085
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 2024
Est. completion date January 2025

Study information

Verified date March 2024
Source Scius Healthcare Solutions Pty Ltd
Contact George M Krassas, B Pharm
Phone +61400950086
Email george@scius.com.au
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an international Delphi study to consolidate expert consensus on the use of respiratory oscillometry in the management of adult patients with asthma or chronic obstructive pulmonary disease (COPD). The primary objective of the Delphi study is to aid the interpretation of respiratory oscillometry in clinical practice amongst adult patients with asthma or COPD. This will be achieved by obtaining expert consensus on: - Which parameters are used in clinical practice for impulse oscillometry (IOS) and for forced oscillation technique (FOT) devices. - What cut-offs can be used for each parameter to guide clinical practice in the management of adult patients with asthma and COPD. This study is based on the Delphi methodology. The Delphi study will comprise of four rounds, one brainstorming round, to formulate the consensus survey, and three rounds to attempt to obtain consensus. In each round a questionnaire comprising of statements and questions regarding respiratory oscillometry will be sent to participants in the Delphi study electronically using SurveyLet, an online survey platform. Participants will respond anonymously to the survey questions, indicating their level of agreement or disagreement with each statement or question. Participants will be given 4 weeks to complete each round of the Delphi study. Questions and statements will be repeated in subsequent rounds until the predefined level of consensus is met or the maximum number of rounds is achieved (limited to a maximum of 3 rounds). Aggregated results for each statement or question, including distribution of results and consensus status, will be provided to participants after each round to facilitate informed decisions in subsequent rounds.


Description:

Study procedures: The Delphi study will comprise of four rounds, one brainstorming round and three rounds to attempt to obtain consensus. A series of anonymous questionnaires will be administered to a panel of experts and respiratory specialists familiar with oscillometry testing. Phase one: Brainstorming to develop survey questionnaire. The initial brainstorming questionnaire will be developed by the Steering Committee, based on the published literature and clinical practice. The brainstorming questionnaire will be circulated to a selected group of respiratory specialists who are known experts in respiratory oscillometry for refinement and testing. The expert panel will comprise of approximately 10 respiratory specialists who have published papers on respiratory oscillometry. This brainstorming questionnaire will be open in nature and will allow all respondents to propose new statements as well as adjust the proposed statements that are to be evaluated by their peers. The results of the brainstorming round will be reviewed by the Steering Committee to finalise the questionnaire for the first round of the Delphi study. Phase two: Attempting to achieve consensus. To obtain consensus three iterative rounds (Rounds 1-3) will be undertaken. In each round a questionnaire comprising of statements and questions regarding respiratory oscillometry will be sent to all participants in the Delphi study electronically using SurveyLet, an online survey platform utilising the Delphi technique. The initial questionnaire for use in Round 1, will be the survey developed in the brainstorming round. There will be a range of statement types used to ascertain consensus, including: - Agreement with statements ranked using a six-point scale (Agree Strongly', ''Agree Moderately', Agree Slightly', 'Disagree Slightly', 'Disagree Strongly', ''Disagree Moderately'). - Agreement on importance/clinical utility of various oscillometry parameters using a ranking process. - Agreement on defining values (cut-offs) for clinically relevant changes for the various oscillometry parameters. Participants will be encouraged to provide free text comments after each statement or question and these comments will be reviewed by the Steering Committee to determine if the questionnaire needs revision prior to the next survey round. Questions and statements will be repeated in subsequent rounds until the predefined level of consensus is met or the maximum number of rounds is achieved (limited to a maximum of 3 rounds). Aggregated results for each statement or question, including distribution of results and consensus status, will be provided to participants after each round to facilitate informed decisions in subsequent rounds. Participants will be given 4 weeks to complete each round of the Delphi study. During a Delphi study, participants with a minority opinion can become discouraged and drop out of the study, potentially resulting in an overestimation of consensus. At the commencement of the study, participants will be sent an email with an encrypted personalised secure link (to the study questionnaire). This secure link means that each participant can only view their own data and the aggregated data shared in study rounds 2 and 3. No study participant nor the lead investigators can see the individual responses of any other participant. Access to subsequent study rounds is also via the encrypted secure link or via the participant login into the SurveyLet platform. In this study, consensus is achieved when ≥ 70% of the participants give the same answer for any question or statement. For questions and statements that are assessed using a 6-point agreement scale, consensus is achieved when ≥ 70% of participants either: - 'Agree Strongly' or ''Agree Moderately' - 'Agree Slightly' or ''Disagree Slightly' - 'Disagree Strongly' or ''Disagree Moderately' For questions and statements that are assessed using a ranking process, consensus is achieved when ≥ 70% of participants give that ranking. For questions and statements that are assessed using a defined value, consensus is achieved when ≥ 70% of participants give the same value.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date January 2025
Est. primary completion date November 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Respiratory specialist in active clinical practice = 12 months. - Use respiratory oscillometry = 2 tests per week Exclusion Criteria: - Only use respiratory oscillometry when participating in clinical trials - Employee or stockholder of pharmaceutical company - Employee or stockholder of oscillometry manufacturer - Employee or stockholder of tobacco/vaping companies.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Respiratory oscillometry
This a Delphi study where we are obtaining expert opinion and input on the use of respiratory oscillometry (a diagnostic respiratory test) in the assessment and management of patients with asthma or chronic obstructive pulmonary disease. The participants are respiratory specialists/pulmonologists. They are sharing their insights into the clinical use of respiratory oscillometry via a series of online surveys. The Delphi process is used in an attempt to achieve consensus as to how respiratory oscillometry is used in clinical practice. As such there is no intervention being used on the study participants, but they are sharing insights on how the respiratory test is used in their clinical practice in order to obtain consensus on this use.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Scius Healthcare Solutions Pty Ltd Chiesi Australia

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of which respiratory oscillometry parameters (resistance, [R5, R20, R5-R20], reactance [X5, delta X5] or reactance area [AX]) are used to guide clinical management of asthma or COPD as determined by expert consensus using a ranking scale. Participants are asked to rank in order of clinical importance the different respiratory oscillometry parameters (R5, R20, X5, AX, R5-R20, delta X5) from 1 to 6
Consensus is achieved when = 70% of the participants give the same ranking order within an individual round of the Delphi study. If consensus is not achieved, aggregated data from the previous round is shared and the participants are asked to provide their ranking again.
When consensus is achieved within an individual Delphi round or through to study end, up to 1 year
Primary Identification of cut-off values used for respiratory oscillometry parameters (R5, X5, AX, R5-R20) to define an abnormal test result as determined by expert consensus using a 6-point categorical scale (Agree strongly to Disagree strongly) Cut-off values used to define abnormality are proposed for each parameter (R5, X5, AX, and R5-R20) and the participants/experts are asked for their level of agreement with the proposed cut-off value being assessed.
An example of the type of statement used for this component of the survey is as follows:
For R5, a result with a z-score > 1.64 is considered abnormal.
A. Agree Strongly B. Agree Moderately C. Agree Slightly D. Disagree Slightly E. Disagree Moderately F. Disagree Strongly
Consensus is achieved when = 70% of the participants give the same level of agreement for each statement within an individual round of the Delphi study. If consensus is not achieved, aggregated data from the previous round is shared and the participants are asked to provide their level of agreement again.
When consensus is achieved within an individual Delphi round or through to study end, up to 1 year
Secondary Identification of cut-off values used for respiratory oscillometry parameters (R5, X5, and AX) to define a bronchodilator response as determined by expert consensus using a 6-point categorical scale (Agree strongly to Disagree strongly) Cut-off values used to define a bronchodilator response are proposed for each parameter (R5, X5, and AX) and the participants/experts are asked for their level of agreement with the proposed cut-off value being assessed.
An example of the type of statement used for this component of the survey is:
For R5, a result with a z-score > 1.4 is considered to be a significant bronchodilator response.
A. Agree Strongly B. Agree Moderately C. Agree Slightly D. Disagree Slightly E. Disagree Moderately F. Disagree Strongly
Consensus is achieved when = 70% of the participants give the same level of agreement for each statement within an individual round of the Delphi study. If consensus is not achieved, aggregated data from the previous round is shared and the participants are asked to provide their level of agreement again.
When consensus is achieved within an individual Delphi round or through to study end, up to 1 year
Secondary Identification of cut-off values used for oscillometry parameters (R5, X5, AX, R5-R20) to define a significant clinical change between visits as determined by expert consensus using a 6-point categorical scale (Agree strongly to Disagree strongly) Cut-off values used to define a significant clinical change between visits are proposed for each parameter (R5, X5, AX and R5-R20) and the participants/experts are asked for their level of agreement with the proposed cut-off value being assessed.
An example of the type of statement used for this component of the survey is:
For R5, a result with a z-score > 0.5 is considered a significant change between visits.
A. Agree Strongly B. Agree Moderately C. Agree Slightly D. Disagree Slightly E. Disagree Moderately F. Disagree Strongly
Consensus is achieved when = 70% of the participants give the same level of agreement for each statement within an individual round of the Delphi study. If consensus is not achieved, aggregated data from the previous round is shared and the participants are asked to provide their level of agreement again.
When consensus is achieved within an individual Delphi round or through to study end, up to 1 year
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device